12th May 2025 11:37
(Alliance News) - N4 Pharma PLC shares jumped on Monday as it reported positive results from the first in vivo study of its proprietary gene delivery system Nuvec for inflammatory bowel disease.
The Derbyshire, England-based pharmaceutical company said the testing on mice evaluated the use of its Nuvec proof-of-concept programme, N4 101, which is an orally delivered anti-inflammatory treatment for inflammatory bowel disease.
Shares in N4 Pharma were up 14% to 0.60 pence in London on Monday morning.
Over a nine-day period, mice with chemically induced acute IBD received single or dual Nuvec-loaded formulations.
N4 Pharma said the results showed reduction in inflammation, with "marked improvements" compared with controls across indicators of colitis, including disease activity index, colon length and body weight loss.
It said there was a marked increase in efficacy achieved with targeting and a sustained therapeutic effect, with a "near complete reduction" in TNF alpha levels in intestinal tissue.
N4 said the results provide clear evidence that Nuvec particles successfully deliver nucleic acid cargos to the gut via oral administration.
"We are delighted with these very promising in vivo data, which demonstrate a sustained anti-inflammatory effect in a validated IBD model - a major milestone for our N4 101 programme. Demonstrating a clear increase in performance through targeting the treatment to specific cells is the holy grail of nucleic acid therapeutics, and these results place Nuvec at the leading edge of nucleic acid delivery technologies," said Chief Executive Officer Nigel Theobald.
Theobald said the work is at an "early stage" but said the data adds to evidence to validate Nuvec as a "novel delivery platform for advanced therapies, strengthening our discussions with commercial partners".
CEO Theobald said: "We look forward to advancing this programme into the next phase of development and providing further updates on this and our broader platform work plans for the coming months in due course."
By Michael Hennessey, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
N4 Pharma Plc